Novel antidotes for target specific oral anticoagulants.

ABSTRACT: Target specific oral anticoagulants (dabigatran, rivaroxaban, apixaban, and edoxaban) are changing the landscape of anticoagulation. The major drawback is the absence of an effective antidote for severe bleedings and/or prior to procedures. Currently there are a few promising antidotes undergoing clinical trials. This review summarized the latest development in idarucizumab, andexanet alpha and PER977.

SUBMITTER: Das A 

PROVIDER: S-EPMC4570637 | biostudies-literature | 2015

REPOSITORIES: biostudies-literature